The goal of this trial is to assess the impact of focal HIFU therapy on quality of life in patients with favourable intermediate-risk localised prostate cancer. The main question it aims to answer is:
What is the prostate cancer-related quality of life in patients with favourable intermediate-risk localised cancer treated by total prostatectomy or focal HIFU ?
Researchers will compare patients with favourable intermediate-risk localised cancer treated by total prostatectomy to patients with favourable intermediate-risk localised cancer treated by focal HIFU to see their quality of life.
Participants will answer EPIC-CP questionnaire 6 months, 12 months and 24 months after treatment
Patient, male, aged between ≥ 40 and ≤ 75 years
Patient with a life expectancy > 10 years at the time of inclusion.
Patient with a therapeutic strategy (prostatectomy or focal HIFU) defined during a PCR.
Patient with a diagnosis of localised prostate cancer at favourable intermediate risk
Patients with a contraindication to MRI
Stage T3a or b on MRI
Patient on long-term anticoagulants and unable to stop them.
Patient already included in another study
Parallel
Total prostatectomy
Procedure/SurgeryTotal prostatectomy is a surgical procedure performed to treat prostate cancer.
Focal HIFU
Procedure/SurgeryFocal HIFU treatment is an innovative technique that consists of destroying prostate tumour cells using high-intensity ultrasound focused exclusively on the affected area of the gland.
Quality of Life in relation to prostate cancer
Quality of life in relation to prostate cancer will be assessed by the total score (ranging from 0 to 60) of the EPIC-CP (Expanded Prostate Cancer Index Composite for Clinical Practice) questionnaire. Higher score means a worse outcome.
Click on the lead sponsor to view all of their trials.
